Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.

Zemni I, Ghalleb M, Jbir I, Slimane M, Ben Hassouna J, Ben Dhieb T, Bouzaiene H, Rahal K.

World J Surg Oncol. 2017 Nov 23;15(1):206. doi: 10.1186/s12957-017-1272-7.


The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

Xin L, Liu YH, Martin TA, Jiang WG.

World J Oncol. 2017 Apr;8(2):34-40. doi: 10.14740/wjon1019w. Epub 2017 May 4. Review.


Molecular Subtypes and Local-Regional Control of Breast Cancer.

Fragomeni SM, Sciallis A, Jeruss JS.

Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005. Review.


Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N.

NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017.


Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.

Janes H, Brown MD, Crager MR, Miller DP, Barlow WE.

Contemp Clin Trials. 2017 Dec;63:30-39. doi: 10.1016/j.cct.2017.08.004. Epub 2017 Aug 14.


Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.

Kamel HFM, Al-Amodi HSAB.

Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13. Review.


Learning from big data: are we undertreating older women with high-risk breast cancer?

Sparano JA, Muss H.

NPJ Breast Cancer. 2016 Jun 8;2:16019. doi: 10.1038/npjbcancer.2016.19. eCollection 2016. No abstract available.


Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.

NPJ Breast Cancer. 2016 Jun 8;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.


Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.

McVeigh TP, Kerin MJ.

Breast Cancer (Dove Med Press). 2017 May 29;9:393-400. doi: 10.2147/BCTT.S109847. eCollection 2017. Review.


Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.


Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D.

Cancer. 2017 Jul 1;123(13):2422-2431. doi: 10.1002/cncr.30618. Epub 2017 Feb 15.


Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.

Kurian AW, Friese CR, Bondarenko I, Jagsi R, Li Y, Hamilton AS, Ward KC, Katz SJ.

JAMA Oncol. 2017 Mar 1;3(3):391-397. doi: 10.1001/jamaoncol.2016.5652.


Incorporate gene signature profiling into routine molecular testing.

Chen N.

Appl Transl Genom. 2013 Apr 11;2:28-33. eCollection 2013 Dec 1. Review.


Estimating the OncotypeDX score: validation of an inexpensive estimation tool.

Eaton AA, Pesce CE, Murphy JO, Stempel MM, Patil SM, Brogi E, Hudis CA, El-Tamer M.

Breast Cancer Res Treat. 2017 Feb;161(3):435-441. doi: 10.1007/s10549-016-4069-4. Epub 2016 Dec 7.


Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.

Bernhardt SM, Dasari P, Walsh D, Townsend AR, Price TJ, Ingman WV.

Front Oncol. 2016 Nov 14;6:241. eCollection 2016. Review.


The analytical validation of the Oncotype DX Recurrence Score assay.

Baehner FL.

Ecancermedicalscience. 2016 Sep 26;10:675. eCollection 2016.


Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.

Mihály Z, Győrffy B.

Microarrays (Basel). 2013 Aug 29;2(3):228-42. doi: 10.3390/microarrays2030228. Review.


The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.

Cockburn JG, Hallett RM, Gillgrass AE, Dias KN, Whelan T, Levine MN, Hassell JA, Bane A.

BMC Cancer. 2016 Jul 28;16:555. doi: 10.1186/s12885-016-2501-0.


Pan-Cancer Analyses Reveal Long Intergenic Non-Coding RNAs Relevant to Tumor Diagnosis, Subtyping and Prognosis.

Ching T, Peplowska K, Huang S, Zhu X, Shen Y, Molnar J, Yu H, Tiirikainen M, Fogelgren B, Fan R, Garmire LX.

EBioMedicine. 2016 May;7:62-72. doi: 10.1016/j.ebiom.2016.03.023. Epub 2016 Mar 19.


Breast cancer multigene testing trends and impact on chemotherapy use.

Ray GT, Mandelblatt J, Habel LA, Ramsey S, Kushi LH, Li Y, Lieu TA.

Am J Manag Care. 2016 May 1;22(5):e153-60.

Supplemental Content

Support Center